|
US6994851B1
(en)
*
|
1997-07-10 |
2006-02-07 |
Mannkind Corporation |
Method of inducing a CTL response
|
|
US6977074B2
(en)
|
1997-07-10 |
2005-12-20 |
Mannkind Corporation |
Method of inducing a CTL response
|
|
US6844188B1
(en)
|
1998-04-08 |
2005-01-18 |
University Of North Carolina At Chapel Hill |
Methods and modified cells for the treatment of cancer
|
|
CA2327835C
(en)
*
|
1998-04-08 |
2010-09-21 |
University Of North Carolina At Chapel Hill |
Methods and modified cells for the treatment of cancer
|
|
ATE384795T1
(de)
*
|
1998-12-31 |
2008-02-15 |
Novartis Vaccines & Diagnostic |
Modifizierte hiv env polypeptide
|
|
AU2221600A
(en)
|
1998-12-31 |
2000-07-31 |
Chiron Corporation |
Improved expression of hiv polypeptides and production of virus-like particles
|
|
EP1141314A2
(en)
*
|
1998-12-31 |
2001-10-10 |
Chiron Corporation |
Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
|
|
US7935805B1
(en)
*
|
1998-12-31 |
2011-05-03 |
Novartis Vaccines & Diagnostics, Inc |
Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
|
|
US8128922B2
(en)
*
|
1999-10-20 |
2012-03-06 |
Johns Hopkins University |
Superior molecular vaccine linking the translocation domain of a bacterial toxin to an antigen
|
|
EP1363938B1
(en)
*
|
2000-08-03 |
2013-12-11 |
Johns Hopkins University |
Molecular vaccine linking an endoplasmic reticulum chaperone polypeptide to an antigen
|
|
GB0026812D0
(en)
*
|
2000-11-02 |
2000-12-20 |
Isis Innovation |
Cancer therapy
|
|
NZ530635A
(en)
*
|
2001-06-15 |
2007-03-30 |
Nordic Vaccine Technology As |
Therapeutical vaccination comprising an immunogen and a targeting vehicle comprising a carrier and a antigen silmilar to the first
|
|
AU2002320314A1
(en)
|
2001-07-05 |
2003-01-21 |
Chiron, Corporation |
Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
|
|
EP1409694A4
(en)
*
|
2001-07-05 |
2006-02-08 |
Chiron Corp |
POLYNUCLEOTIDES ENCODING ANTIGENIC POLYPEPTIDES OF HIV SUBTYPE B AND / OR SUBTYPE C, POLYPEPTIDES AND USES THEREOF
|
|
CA2458995C
(en)
*
|
2001-08-31 |
2013-04-30 |
Chiron Corporation |
Polynucleotides encoding antigenic hiv type b polypeptides, polypeptides and uses thereof
|
|
US20030170614A1
(en)
*
|
2001-08-31 |
2003-09-11 |
Megede Jan Zur |
Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof
|
|
SI1620456T1
(sl)
*
|
2003-04-18 |
2014-05-30 |
Biotech Synergy, Inc. |
Hla-a2 s tumorjem povezan antigen peptidov in sestavki
|
|
EP1644048B1
(en)
*
|
2003-05-05 |
2015-04-29 |
Johns Hopkins University |
Anti-cancer dna vaccine employing plasmids encoding signal sequence, mutant oncoprotein antigen, and heat shock protein
|
|
US7807187B2
(en)
*
|
2003-05-13 |
2010-10-05 |
The University Of Massachusetts |
Endogenous adjuvant molecules and uses thereof
|
|
AU2005327198B2
(en)
*
|
2004-07-09 |
2011-03-31 |
University Of North Carolina At Chapel Hill |
Viral adjuvants
|
|
WO2006073970A2
(en)
*
|
2005-01-06 |
2006-07-13 |
The Johns Hopkins University |
Rna interference that blocks expression of pro-apoptotic proteins potentiates immunity induced by dna and transfected dendritic cell vaccines
|
|
WO2006081323A2
(en)
*
|
2005-01-26 |
2006-08-03 |
The Johns Hopkins University |
Anti-cancer dna vaccine employing plasmids encoding mutant oncoprotein antigen and calreticulin
|
|
EP1856250B1
(en)
*
|
2005-02-15 |
2013-07-24 |
The University of North Carolina At Chapel Hill |
New live virus vaccines
|
|
US20100330105A1
(en)
*
|
2006-08-22 |
2010-12-30 |
John Hopkins University |
Anticancer Combination Therapies
|
|
US9085638B2
(en)
|
2007-03-07 |
2015-07-21 |
The Johns Hopkins University |
DNA vaccine enhancement with MHC class II activators
|
|
US20080260765A1
(en)
*
|
2007-03-15 |
2008-10-23 |
Johns Hopkins University |
HPV DNA Vaccines and Methods of Use Thereof
|
|
US20090285861A1
(en)
*
|
2008-04-17 |
2009-11-19 |
Tzyy-Choou Wu |
Tumor cell-based cancer immunotherapeutic compositions and methods
|
|
WO2011119920A2
(en)
|
2010-03-25 |
2011-09-29 |
Oregon Health & Science University |
Cmv glycoproteins and recombinant vectors
|
|
ES2667425T3
(es)
|
2011-06-10 |
2018-05-10 |
Oregon Health & Science University |
Glucoproteínas y vectores recombinantes de CMV
|
|
AU2012216792A1
(en)
|
2011-09-12 |
2013-03-28 |
International Aids Vaccine Initiative |
Immunoselection of recombinant vesicular stomatitis virus expressing HIV-1 proteins by broadly neutralizing antibodies
|
|
EP2586461A1
(en)
|
2011-10-27 |
2013-05-01 |
Christopher L. Parks |
Viral particles derived from an enveloped virus
|
|
EP2679596B1
(en)
|
2012-06-27 |
2017-04-12 |
International Aids Vaccine Initiative |
HIV-1 env glycoprotein variant
|
|
US20150065381A1
(en)
|
2013-09-05 |
2015-03-05 |
International Aids Vaccine Initiative |
Methods of identifying novel hiv-1 immunogens
|
|
EP2873423B1
(en)
|
2013-10-07 |
2017-05-31 |
International Aids Vaccine Initiative |
Soluble hiv-1 envelope glycoprotein trimers
|
|
US10174292B2
(en)
|
2015-03-20 |
2019-01-08 |
International Aids Vaccine Initiative |
Soluble HIV-1 envelope glycoprotein trimers
|
|
EP3072901A1
(en)
|
2015-03-23 |
2016-09-28 |
International Aids Vaccine Initiative |
Soluble hiv-1 envelope glycoprotein trimers
|
|
US11559504B2
(en)
*
|
2017-06-02 |
2023-01-24 |
The Penn State Research Foundation |
Ceramide nanoliposomes, compositions and methods of using for immunotherapy
|
|
EP4014988A4
(en)
*
|
2019-08-13 |
2023-11-29 |
National Institutes of Biomedical Innovation, Health and Nutrition |
NOVEL TREATMENT AND PREVENTION OF A DISEASE BASED ON AN IMMUNOLOGICAL MEMORY
|